Literature DB >> 21934551

Impact of histological response after neoadjuvant chemoradiotherapy on recurrence-free survival in UICC-T3 pancreatic adenocarcinoma but not in UICC-T4.

Yasuhiro Murata1, Shugo Mizuno, Masashi Kishiwada, Takashi Hamada, Masanobu Usui, Hiroyuki Sakurai, Masami Tabata, Hiroyuki Inoue, Taizo Shiraishi, Shuji Isaji.   

Abstract

OBJECTIVES: Although the prognostic benefit of neoadjuvant chemoradiotherapy (NCRT) against pancreatic cancer has been indicated by several reports, it is controversial whether histological response is associated with prognosis. The objective was to explore the relationship between histological response and prognosis in T3 and T4 pancreatic adenocarcinoma.
METHODS: We histologically examined the resected specimens obtained from 58 patients (T3, n = 40; and T4, n = 18) for whom we performed curative-intent resection after NCRT. Histological response was evaluated according to Evans's criteria to determine whether it influenced survival.
RESULTS: In T3 tumors, 13 (32.5%) belonged to high responders (tumor destruction of >50%) (R0, n = 13) and 27 (67.5%) belonged to low responders (tumor destruction of ≤50%) (R0, n = 22, R1, n = 3, R2, n = 2). Recurrence-free survival rate was significantly higher in high responders than in low responders (3-year recurrence-free survival rates: 71.3% vs 13.1%, P = 0.0095). In T4 tumors, however, only 1 (5.6%) was a high responder, and R0 resection was obtained only in 5 patients (27.8%).
CONCLUSIONS: In T3 tumors, histological response is considered a significant prognostic indicator, securing the surgical margin, whereas in T4 tumors, NCRT did not provide beneficial histological response, not securing the surgical margin.

Entities:  

Mesh:

Year:  2012        PMID: 21934551     DOI: 10.1097/MPA.0b013e3182236442

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  13 in total

1.  Diffusion-weighted MRI predicts the histologic response for neoadjuvant therapy in patients with pancreatic cancer: a prospective study (DIFFERENT trial).

Authors:  Ken-Ichi Okada; Manabu Kawai; Seiko Hirono; Fumiyoshi Kojima; Kensuke Tanioka; Masaki Terada; Motoki Miyazawa; Yuji Kitahata; Yoshifumi Iwahashi; Masaki Ueno; Shinya Hayami; Shin-Ichi Murata; Toshio Shimokawa; Hiroki Yamaue
Journal:  Langenbecks Arch Surg       Date:  2020-01-28       Impact factor: 3.445

2.  Margin-negative limited resection of metastatic pancreatic tumors from rectal cancer preoperatively diagnosed by endoscopic ultrasound-guided fine-needle aspiration biopsies: report of two cases.

Authors:  Akihiro Tanemura; Shugo Mizuno; Yasuo Okura; Hiroyuki Inoue; Haruyuki Takaki; Keisuke Nishimura; Katsunori Uchida; Shuji Isaji
Journal:  Surg Today       Date:  2012-11-11       Impact factor: 2.549

3.  Concurrent gemcitabine+S-1 neoadjuvant chemotherapy contributes to the improved survival of patients with small borderline-resectable pancreatic cancer tumors.

Authors:  Toshihiko Masui; Ryuichiro Doi; Yoshiya Kawaguchi; Asahi Sato; Kenzo Nakano; Tatsuo Ito; Takayuki Anazawa; Kyoichi Takaori; Shinji Uemoto
Journal:  Surg Today       Date:  2016-02-09       Impact factor: 2.549

4.  Anterior approach to the superior mesenteric artery by using nerve plexus hanging maneuver for borderline resectable pancreatic head carcinoma.

Authors:  Shugo Mizuno; Shuji Isaji; Akihiro Tanemura; Masashi Kishiwada; Yasuhiro Murata; Yoshinori Azumi; Naohisa Kuriyama; Masanobu Usui; Hiroyuki Sakurai; Masami Tabata
Journal:  J Gastrointest Surg       Date:  2014-03-25       Impact factor: 3.452

5.  Impact of histological response after neoadjuvant therapy on podocalyxin as a prognostic marker in pancreatic cancer.

Authors:  Annika Eurola; Ari Ristimäki; Harri Mustonen; Anna-Maria Nurmi; Jaana Hagström; Caj Haglund; Hanna Seppänen
Journal:  Sci Rep       Date:  2021-05-10       Impact factor: 4.379

6.  Outcomes of Neoadjuvant Chemotherapy Versus Chemoradiation in Localized Pancreatic Cancer: A Case-Control Matched Analysis.

Authors:  Asmita Chopra; Jacob C Hodges; Adam Olson; Steve Burton; Susannah G Ellsworth; Nathan Bahary; Aatur D Singhi; Brian A Boone; Joal D Beane; David Bartlett; Kenneth K Lee; Melissa E Hogg; Michael T Lotze; Alessandro Paniccia; Herbert Zeh; Amer H Zureikat
Journal:  Ann Surg Oncol       Date:  2020-11-24       Impact factor: 4.339

7.  Survival Analysis in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Chemoradiotherapy Followed by Surgery According to the International Consensus on the 2017 Definition of Borderline Resectable Cancer.

Authors:  Aoi Hayasaki; Shuji Isaji; Masashi Kishiwada; Takehiro Fujii; Yusuke Iizawa; Hiroyuki Kato; Akihiro Tanemura; Yasuhiro Murata; Yoshinori Azumi; Naohisa Kuriyama; Shugo Mizuno; Masanobu Usui; Hiroyuki Sakurai
Journal:  Cancers (Basel)       Date:  2018-03-05       Impact factor: 6.639

8.  Superiority of stapled side-to-side gastrojejunostomy over conventional hand-sewn end-to-side gastrojejunostomy for reducing the risk of primary delayed gastric emptying after subtotal stomach-preserving pancreaticoduodenectomy.

Authors:  Yasuhiro Murata; Akihiro Tanemura; Hiroyuki Kato; Naohisa Kuriyama; Yoshinori Azumi; Masashi Kishiwada; Shugo Mizuno; Masanobu Usui; Hiroyuki Sakurai; Shuji Isaji
Journal:  Surg Today       Date:  2017-03-23       Impact factor: 2.549

9.  Clinical Significance of Plasma Apolipoprotein-AII Isoforms as a Marker of Pancreatic Exocrine Disorder for Patients with Pancreatic Adenocarcinoma Undergoing Chemoradiotherapy, Paying Attention to Pancreatic Morphological Changes.

Authors:  Aoi Hayasaki; Yasuhiro Murata; Masanobu Usui; Taemi Hibi; Takehiro Fujii; Yusuke Iizawa; Hiroyuki Kato; Akihiro Tanemura; Yoshinori Azumi; Naohisa Kuriyama; Masashi Kishiwada; Shugo Mizuno; Hiroyuki Sakurai; Katsunori Uchida; Shuji Isaji
Journal:  Biomed Res Int       Date:  2019-04-04       Impact factor: 3.411

10.  Gemcitabine-based chemoradiotherapy followed by surgery for borderline resectable and locally unresectable pancreatic ductal adenocarcinoma: significance of the CA19-9 reduction rate and intratumoral human equilibrative nucleoside transporter 1 expression.

Authors:  Motoyuki Kobayashi; Shugo Mizuno; Yasuhiro Murata; Masashi Kishiwada; Masanobu Usui; Hiroyuki Sakurai; Masami Tabata; Noriko Ii; Koichiro Yamakado; Hiroyuki Inoue; Taizo Shiraishi; Tomomi Yamada; Shuji Isaji
Journal:  Pancreas       Date:  2014-04       Impact factor: 3.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.